D.A. Davidson & CO. lessened its holdings in shares of Davis Select U.S. Equity ETF (NASDAQ:DUSA – Get Rating) by 2.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 131,695 shares of the healthcare company’s stock after selling 2,807 shares […]
LAS VEGAS, March 3, 2022 /PRNewswire/ The Actinic Keratosis Treatment Drugs produced by drug giants of the pharmaceuticals industry such as VDA-1102 (Vidac Pharma), DFD-07 (Promius Pharma)
/PRNewswire/ The Actinic Keratosis Treatment Drugs produced by drug giants of the pharmaceuticals industry such as VDA-1102 (Vidac Pharma), DFD-07 (Promius.
/PRNewswire/ The "Light Activated Therapies Market: Focus on Photodynamic Therapies, Photoimmunotherapies and Photothermal Therapies - Distribution by.
ADVERTISEMENT
Review Group Slams Specious Sun Pharma Skin Drug Patent
Law360 (July 26, 2021, 8:15 PM EDT) Sun Pharmaceutical s patent for Levulan Kerastick, which uses light photodynamic therapy to treat skin conditions, seems to be an inequitable extension of valid patent rights granted by the U.S. government, according to a new report issued Monday.
The report by International Patent Reviews LLC, a group that says it is focused on identifying patents filed by drugmakers that don t represent novel inventions stated that Sun Pharma has been unfairly holding on to the technology surrounding Levulan Kerastick for about 46 years.
Sun Pharma filed a new drug application for Levulan Kerastick in 1998, and the latest patent on the company s.